FDMT240719P17500
- 1.00
- 0.000.00%
4D Molecular Therapeutics Newsroom
BMO Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $40
BMO Capital analyst Kostas Biliouris maintains $4D Molecular Therapeutics(FDMT.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Domino's Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results.The company reported second-quarter FY24 sales growth of 7.1% year-
Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights
In the preceding three months, 5 analysts have released ratings for 4D Molecular Therapeutics (NASDAQ:FDMT), presenting a wide array of perspectives from bullish to bearish.Summarizing their recent
4D Molecular Therapeutics Is Maintained at Outperform by BMO Capital
4D Molecular Therapeutics Is Maintained at Outperform by BMO
A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $38 to $82
On Jul 18, major Wall Street analysts update their ratings for $4D Molecular Therapeutics(FDMT.US)$, with price targets ranging from $38 to $82.BofA Securities analyst Tazeen Ahmad maintains with a
Express News | 4D Molecular Therapeutics Inc : BMO Cuts Target Price to $40 From $63
Strong Buy Rating for 4D Molecular Therapeutics Backed by Promising WAMD Treatment Efficacy and Safety
4DMT Shares Are Trading Lower. The Company Announced the Presentation of Phase 2 PRISM Interim Data.
4DMT Shares Are Trading Lower. The Company Announced the Presentation of Phase 2 PRISM Interim Data.
Express News | 4DMT Shares Are Trading Lower. The Company Announced the Presentation of Phase 2 PRISM Interim Data
4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital
4D Molecular Therapeutics Is Maintained at Buy by Chardan
4D Molecular Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/17/2024 117.27% Chardan Capital $38 → $38 Maintains Buy 06/26/2024 128.7% RBC Capital $40 → $40
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for
Buy Rating for 4D Molecular Therapeutics Based on Promising Phase II Trial Results for 4D-150 Gene Therapy
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Applied Therapeutics (APLT) and Oric Pharmaceuticals (ORIC)
4D Molecular Therapeutics Falls 30% Following Phase 2 Wet AMD Candidate Data
Express News | 4D Molecular Therapeutics Inc : Leerink Partners Raises Target Price to $41 From $35
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday
Health care stocks were leaning lower premarket Wednesday, with the Health Care Select Sector SPDR Fund (XLV) declining 0.8% and the iShares Biotechnology ETF (IBB) down 1.1% recently.4D Molecular
Sector Update: Health Care
Health care stocks were flat to lower premarket Wednesday with the Health Care Select Sector SPDR Fund (XLV) unchanged and the iShares Biotechnology ETF (IBB) down 0.8% recently.4D Molecular
4D Molecular Therapeutics Presents Phase 2 Trial Results for Wet AMD at ASRS Meeting
4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive initial interim 24-week landmark data from the Population Extension cohort of the PRISM Phase 2 Clinical Trial, which evaluated intravitreal 4D-150 in a broad wet AMD patient population.
Express News | 4D Molecular Therapeutics Inc - 4D-150 Shows 89% Reduction in Annualized Injection Rate